NCT03219502View on ClinicalTrials.gov

rTMS in Improving Neuropathy in Patients With Stage I-IV Cancer Who Have Received Oxaliplatin Chemotherapy

NAActive, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Malignant NeoplasmNeuropathy
Interventions
OTHER

Best Practice

Receive standard of care

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Repetitive Transcranial Magnetic Stimulation

Undergo rTMS

PROCEDURE

Sham Intervention

Undergo sham rTMS

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03219502 - rTMS in Improving Neuropathy in Patients With Stage I-IV Cancer Who Have Received Oxaliplatin Chemotherapy | Biotech Hunter | Biotech Hunter